DNA Testing Market Growth Driven by 7.4% CAGR, Fueled by Oncology Diagnostics and Direct-to-Consumer Kits Surge

According to DataM Intelligence, the DNA Testing Market Size is growing at a CAGR of 7.4% from 2024 to 2031. The escalating demand for personalized medicine, oncology diagnostics, and direct-to-consumer genealogy testing is propelling adoption of advanced genetic analysis platforms. These non-invasive, high-throughput systems equipped with NGS, PCR, and microarray technologies deliver rapid, actionable insights for clinical decision-making, prenatal screening, and ancestry tracing, bypassing traditional lengthy lab workflows.
By integrating SNP-based prenatal panels, liquid biopsy assays, and AI-driven variant interpretation, DNA testing enables precise risk stratification and therapeutic guidance across oncology, infectious diseases, and reproductive health.

Growth Drivers
✦ Global cancer incidence projected at 19.3 million new cases in 2024 (IARC), driving oncology genetic testing demand for hereditary risk assessment and targeted therapies.
✦ Direct-to-consumer (DTC) kits surged 28% YoY in 2024, fueled by ancestry and wellness segments reaching 35 million users worldwide.
✦ Personalized medicine market valued at USD 87 billion in 2024, with DNA profiling integral to 45% of new FDA-approved drugs.
✦ Prenatal non-invasive testing (NIPT) adoption rose 22% in emerging markets, supported by declining NGS costs (down 15% annually).
✦ Government initiatives in Asia-Pacific allocated USD 2.1 billion for genetic screening programs targeting rare diseases and carrier status.

Download PDF Brochure:
https://www.datamintelligence.com/download-sample/dna-testing-market?sindhuri

Browse in-depth TOC on "DNA Testing Market"
45+ - Tables
40+ - Figures
180 - Pages

Market Segmentation Analysis

By Product Type
The market is segmented into Instruments, Reagents, and Software & Services.
Reagents dominate with 48% market share in 2024, driven by consumable kits for PCR and NGS workflows in high-volume diagnostic labs.
Instruments hold 32%, led by sequencers and mass spectrometers for research and clinical oncology. Software & Services account for 20%, surging with cloud-based bioinformatics and genetic counseling platforms.

By Technology
PCR leads with 40% share, foundational for infectious disease and prenatal panels. Sequencing Technology (NGS) commands 35%, core to oncology liquid biopsies and whole-exome analysis. In situ hybridization (12%), Mass Spectrometry (8%), and Others (5%) support niche applications like pharmacogenomics.

By Application
Oncology holds 38% share and fastest CAGR (8.1%), propelled by companion diagnostics and tumor profiling. Infectious Disease Testing (22%) spikes with pathogen genomics. Myogenic Disorder Diagnosis (15%), Clinical Diagnosis Confirmation (12%), Prenatal & Pre-implantation Diagnosis (10%), and Others (3%) round out preventive and reproductive segments.

By End-User
Diagnostic Centers dominate with 45% share, scaling centralized NGS hubs. Point of Care (30%) grows fastest at 9.2% CAGR via rapid PCR devices. Self Testing/OTC (25%) expands through DTC ancestry and health kits.

Request for Customized Sample Report as per Your Business Requirement:
https://www.datamintelligence.com/customize/dna-testing-market?sindhuri
Regional Insights

North America
North America holds the largest share (42% in 2024), driven by FDA approvals, reimbursement for NIPT, and DTC leaders like 23 and Me.
U.S. oncology genetic testing volume grew 25% in 2024; CMS expanded coverage for hereditary cancer panels.Over 70% of IVF clinics adopted pre-implantation genetic screening.Canada invested USD 850 million in national genomics infrastructure.

Asia-Pacific
Fastest-growing region at 9.5% CAGR, led by population-scale screening and medical tourism.
India launched 50 new genetic labs under Ayushman Bharat, targeting 100 million screenings by 2030.China sequenced 1.2 million genomes in 2024 via BGI partnerships.
Japan and South Korea drove 32% YoY growth in consumer ancestry testing.

Competitive Landscape

According to DataM Intelligence, the DNA Testing Market is moderately competitive, with sequencing giants and diagnostic innovators expanding NGS capacity and DTC channels.

Key Players:

✦ Illumina, Inc. launched NovaSeq X Plus in 2024, cutting sequencing costs by 50% for population studies.
✦ Thermo Fisher Scientific reported 20% YoY growth from Oncomine Dx targeted panels.
✦ Qiagen introduced AI-powered QCI Interpret for variant classification, reducing report time by 40%.
✦ Natera expanded Panorama NIPT globally, achieving 98% accuracy in twin pregnancies.
✦ Roche Diagnostics integrated FoundationOne liquid biopsy with Navify platform for real-time oncology insights.
✦ Abbott Laboratories enhanced Alinity systems for point-of-care infectious disease PCR.
✦ Bio-Rad Laboratories rolled out droplet digital PCR for minimal residual disease monitoring.
✦ Hologic Inc. secured FDA breakthrough designation for HPV genotyping assays.
✦ Siemens Healthineers partnered with pathology networks for automated DNA extraction workflows.
✦BGI Genomics opened joint lab in Hungary, accelerating European market entry.

Recent Developments
✦Illumina partnered with AstraZeneca for multi-cancer early detection trials (Q2 2024).
✦Natera launched Signatera MRD test in 15 new countries (Q3 2024).
✦Thermo Fisher acquired Henniges for USD 1.2 billion to bolster reagent supply chain (Jan 2025).
✦Qiagen integrated GeneGlobe design tool with 10,000+ pre-validated assays (Apr 2025).
✦Roche received CE mark for cobas HPV self-collection kit (Mar 2025).

Market Outlook and Opportunities
The market stands at an inflection point as genomic data explodes and costs plummet.

Key Forecast Indicators:
✦ Asia-Pacific to reach 30% global share by 2030, overtaking Europe.
✦ Oncology segment revenue to exceed USD 12 billion by 2031.
✦ NGS technology to maintain 40%+ dominance through 2031.
✦ DTC/self-testing to contribute 35% incremental growth via wellness and pharmacogenomics.
✦ AI-integrated interpretation platforms to unlock USD 3 billion in bioinformatics opportunities by 2031.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer):
https://www.datamintelligence.com/buy-now-page?report=dna-testing-market?sindhuri

Conclusion

The Global DNA Testing Market is evolving from diagnostic novelty to cornerstone of precision healthcare. With a steady 7.4% CAGR through 2031, advanced platforms are bridging critical gaps in cancer care, reproductive health, and population genomics.

According to DataM Intelligence, leaders like Illumina, Thermo Fisher, and Natera supported by innovators such as Qiagen and Roche are scaling high-throughput, affordable solutions that democratize genetic insights. As chronic disease burdens rise and consumer empowerment accelerates, DNA testing is poised to become routine infrastructure for proactive medicine by 2031.

Contact:
Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as water technologies and sustainable infrastructure. To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.